Posts tagged brain
In conversation with Hrishikesh Suresh of NeuroGate

As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six-year residency in neurosurgery. But since the age of 12, he has had a passion for computer coding and, as a result, contributed to the company’s software development, which aims to capture motion data as a method to diagnose neurodegenerative diseases...

Read More
Titan’s next ProNeura-based implant dovetails with PD awareness month

After receiving FDA approval last year for its Probuphine implant as a maintenance treatment for opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is employing its ProNeura drug delivery technology to develop an implant to treat Parkinson’s disease.

Read More
IntelGenx sees 2017 milestones as transformational

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has multiple milestones on tap this year with its oral film drug delivery platform, VersaFilm, as it continues building strategic partnerships in the pharmaceutical industry.

Read More
Athersys poised to launch pivotal stroke study next summer

After receiving a Special Protocol Assessment (SPA) from the FDA at the end of September, Athersys (NASDAQ:ATHX) hopes to launch a pivotal trial next summer administering its intravenous MultiStem cell therapy in patients following an ischemic stroke.

Read More
NeuroproteXeon targets Q2 start of Phase 3 Xenex trial

Closely-held NeuroproteXeon has received agreement on a special protocol assessment from the FDA for a Phase 3 trial of its inhaled pharmaceutical grade product, XENEX, a xenon gas formulation, as a neuroprotecter against brain cell death following acute neurologic injury, such as cardiac arrest.

Read More
Lupus Foundation puzzled by negative reaction to Aurinia data

As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of directors and the lupus research community to bring national attention and resources to lupus research and education. Ms. Raymond came to the LFA after serving as the founding CEO of the National Osteoporosis Foundation, beginning in 1986. She envisions great progress in lupus treatment and care over the next 10 years but recognizes the urgent need to elevate lupus on the national healthcare agenda by increasing federal and private investment in research on lupus and developing constructive public policies aimed at bringing support and services to all people affected by lupus. In this interview with BioTuesdays.com, Ms. Raymond discusses the state of the disease and results of a recent clinical study by Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP).

Read More
FeatureLeonard ZehrThe Lupus Foundation of America, LFA, Sandra Raymond, lupus research community, National Osteoporosis Foundation, lupus treatment, national health care, Aurinia Pharmaceuticals, Aurinia, NASDAQ:AUPH, NASDAQ, AUPH, TSX:AUP, TSX, AUP, autoimmune disease, immune system, healthy tissues, inflammation, organ damage, life-threatening, treatments, joint damage, skin rashes, extreme fatigue, hair loss, kidneys, lungs, cardiovascular, brain, disease flares, treatment regimens, mortality, genetics, hormonal factors, environmental triggers, imbalance, bacteria, organ, tissue, sun exposure, lupus, lupus flares, butterfly-shaped rash, cheeks, bridge of the nose, organ systems, mortality statistics, renal disease, cardiovascular disease, infections, memorial donations, pioneering physicians, steroids, chemotherapies, Benlysta, mouth sores, hyperactive immune system, osteoporosis, bone fractures, insomnia, diabetes, infertility, blood system, nervous system, disorders, breast cancer, breast cancer patients, lupus kidney disease, chemo, tissue damage, kidney disease, lupus nephritis, Phase 2 trial, Phase 3 trial, Aurinia’s voclosporin, scientific literature, Bristol Myers-Squibb’s trial, Abatacept, mycophenolate mofetil, Asia, research initiatives, national and international awareness campaigns, fostered national legislation, education programs, biology, new medications, private sector, FDA, clinical trials, disease activity instrument, questionnaire, global biopharmaceutical company, global movement
Kadimastem plans stem cell therapy trial for ALS in late 2016

Kadimastem (TASE:KDST) hopes its pre-IND meeting with the FDA in November will outline a protocol for a Phase 1/2a clinical trial of its stem cell therapy for the treatment for Amyotrophic Lateral Sclerosis (ALS) to begin at the end of 2016.

“Our plan is to begin the trial in Israel under an IND and then continue it in the U.S.,” Arik Hasson, EVP for R&D, says in an interview with BioTuesdays.com.

Dr. Hasson explains that Kadimastem’s technology platform enables the differentiation of stem cells into a range of functional human cells for regenerative medicine, including neuron-supporting cells of the brain for diseases of the central nervous system, such as ALS, as well as pancreatic cells that produce and secrete insulin for Type 1 diabetic patients.

Read More